Company Performance Metrics
Single Dose Therapeutics develops neuroplastogen drug candidates intended to address maladaptive learning, enhance psychological resilience, and support cognitive health in psychiatric and neurodegenerative conditions. The company focuses on advancing these compounds through preclinical research and clinical development. Its lead candidate SD-A001
is a preclinical pharmacotherapy for stimulant use disorder, evaluated for initiating neuroadaptive processes in neural circuits involved in learning and behavioral regulation. SD-A001 is designed to enhance neuroplasticity without inducing psychotomimetic effects. The pipeline also includes SD-A012, in preclinical development for Parkinson’s disease. Single Dose Therapeutics concentrates on transforming these investigational drugs into treatment options for conditions with limited existing therapies and those that currently require chronic treatment.
